Firmagon (Degarelix) Intermittent Therapy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
Men with localized prostate cancer requiring intermittent androgen deprivation therapy for biochemical recurrence following radical therapy will be asked to participate in a phase 4 safety and efficacy clinical trial comparing 10 months versus 4 months of degarelix (Firmagon®) therapy with the endpoint of prolonging the off treatment interval.
Epistemonikos ID: 4d0f84373bd358d785fda01940f0604fd4780501
First added on: May 10, 2024